Morphic Holding, Inc(NASDAQ:MORF) 
Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a47-specific integrin inhibitor affec...
Website: http://www.morphictx.com
Founded: 2014
IPO Price: $15 (Jun 27, 2019)
Full Time Employees: 87
CEO: Praveen P. Tipirneni
Sector: Healthcare
Industry: Biotechnology
The information provided in this report is taken from www.sec.gov. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Day
Week
Month
Date 2024-02-20
P
O 37.10
H 38.14
L 35.47
C 35.92
V 581,477
10EMA 35.92
20EMA 35.92
60EMA 35.92
120EMA 35.92
250EMA 35.92